- FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade
- FDA Approves Genentech’s Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for The Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
- FDA Approves RediTrex (methotrexate) for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Psoriasis
- FDA Approves Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease
- FDA Approves Exservan (riluzole) Oral Film for the Treatment of Amyotrophic Lateral Sclerosis
- FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia
- FDA Approves Xcopri (cenobamate) for the Treatment of Partial-Onset Seizures in Adult Patients
- FDA Approves Xcopri (cenobamate) for the Treatment of Partial-Onset Seizures in Adults
- FDA Approves Givlaari (givosiran) for Acute Hepatic Porphyria
- FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
- FDA Approves Adakveo (crizanlizumab-tmca) to Reduce Frequency of Pain Crises in Individuals Living with Sickle Cell Disease
- FDA Approves Fetroja (cefiderocol) for the Treatment of Complicated Urinary Tract Infections
- FDA Approves Brukinsa (zanubrutinib) for the Treatment of Mantle Cell Lymphoma
- FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
- FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta